中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

57 records (took 0.021 seconds)

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    31.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 审中-公开

    公开(公告)号：US20180161396A1

    公开(公告)日：2018-06-14

    申请号：US15834633

    申请日：2017-12-07

    Applicant: immatics biotechnologies GmbH

    Inventor： Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER ,  Claudia WAGNER

    IPC: A61K38/17 ,  A61K35/17 ,  C07K14/725 ,  C12N15/85 ,  A61P35/00

    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    32.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 审中-公开

    公开(公告)号：US20180051080A1

    公开(公告)日：2018-02-22

    申请号：US15677651

    申请日：2017-08-15

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Leonie ALTEN ,  Dominik MAURER ,  Steffen WALTER ,  Sebastian BUNK

    IPC: C07K16/28

    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

    STABILIZED MHC MOLECULES
    34.
    发明申请
    STABILIZED MHC MOLECULES 有权

    公开(公告)号：US20240409607A1

    公开(公告)日：2024-12-12

    申请号：US18701949

    申请日：2022-10-18

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Thomas TREIBER ,  Stefanie SPALT ,  Dominik MAURER

    IPC: C07K14/74 ,  A61K9/08 ,  A61K47/12

    Abstract: The present invention relates to a composition comprising a major histocompatibility complex (MHC) protein, and an R1—COOH or salt thereof. The invention further relates to the use of an R1—COOH or salt thereof, for stabilizing an MHC protein. The invention also relates to a method for stabilizing an MHC protein. The invention also relates to a kit comprising an MHC protein, and an R1—COOH or salt thereof.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    37.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20230132241A1

    公开(公告)日：2023-04-27

    申请号：US17793237

    申请日：2020-01-15

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Sebastian BUNK ,  Martin HOFMANN ,  Meike HUTT ,  Dominik MAURER ,  Gabriele PSZOLLA ,  Frank SCHWOEBEL ,  Felix UNVERDORBEN ,  Claudia WAGNER ,  Sara YOUSEF

    IPC: C07K16/30 ,  C12N15/63 ,  A61P35/00

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are selective and specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 8 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    38.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20220372165A1

    公开(公告)日：2022-11-24

    申请号：US17736882

    申请日：2022-05-04

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

    IPC: C07K16/30 ,  C07K16/46 ,  C07K16/28

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE
    39.
    发明申请
    RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE 有权

    公开(公告)号：US20210032370A1

    公开(公告)日：2021-02-04

    申请号：US16943313

    申请日：2020-07-30

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Felix UNVERDORBEN ,  Meike HUTT ,  Dominik MAURER ,  Sebastian BUNK

    IPC: C07K16/46 ,  C07K16/28 ,  C07K16/32

    Abstract: The present invention concerns bispecific antigen binding proteins directed against MHC presented target antigens (TA). The invention in particular provides bispecific antigen binding proteins comprising at least two antigen binding sites (A and B), wherein the antigen binding site A binds to CD3 and the antigen binding site B binds to a target antigenic (TA) peptide/MHC complex. The bispecific antigen binding proteins of the invention comprise, in particular, the CDRs of the VL and VH domains of novel engineered anti-CD3 antibodies having a reduced affinity. The bispecific antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of TA associated diseases, such as tumor-associated antigen (TAA) expressing cancerous diseases. Further provided are nucleic acids encoding the bispecific antigen binding protein of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding protein and pharmaceutical compositions comprising the bispecific antigen binding proteins of the invention.

    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
    40.
    发明申请
    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS 审中-公开

    公开(公告)号：US20200339652A1

    公开(公告)日：2020-10-29

    申请号：US16813248

    申请日：2020-03-09

    Applicant: IMMATICS BIOTECHNOLOGIES GMBH

    Inventor： Dominik MAURER ,  Sebastian BUNK ,  Leonie ALTEN

    IPC: C07K14/725 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10

    Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Patent Agency Ranking